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Abstract
The platelet inhibitory effects of the Phase 3 anticancer agent and nitric oxide (NO)
donor, RRx‐001, (1‐bromoacetyl‐3,3‐dinitroazetidine) were examined ex vivo and com-
pared with the diazeniumdiolate NO donor, diethylenetriamine NONOate (DETA‐NON-
Oate), which spontaneously releases nitric oxide in aqueous solution. In the absence of
red blood cells and in a dose‐dependent manner, DETA‐NONOate strongly inhibited
platelet aggregation induced by several stimuli (ADP, epinephrine and collagen) whereas
RRx‐001 only slightly inhibited platelet aggregation under the same conditions in a
dose‐dependent manner; these antiaggregant effects were blocked when both DETA‐
NONOate and RRx‐001 were co‐incubated with carboxy‐PTIO (CPTIO 0.01‐100 micro-
mol), a widely accepted NO scavenger. However, in the presence of red blood cells from
healthy human donors, RRx‐001, which binds covalently to haemoglobin (Hb) and catal-
yses the production of NO from endogenous nitrite, more strongly inhibited the aggre-
gation of platelets than DETA‐NONOate in a dose‐dependent manner likely because
haemoglobin avidly scavenges nitric oxide and reduces its half‐life; the RRx‐001‐
mediated platelet inhibitory effect was increased in the presence of nitrite. The results
of this study suggest that RRx‐001‐bound Hb (within RBCs) plays an important role in
the bioconversion of NO2 to NO
., which makes RRx‐001 a more physiologically relevant
inhibitor of platelet aggregation than other nitric oxide donors, whose effects are atten-
uated in the presence of red blood cells. Therefore, RRx‐001‐mediated platelet inhibi-
tion is a potentially useful therapeutic property, especially in hypercoagulable cancer
patients that are at an increased risk of thrombotic complications.
K E YWORD S
cancer, haemoglobin, nitric oxide, red blood cells, RRx-001
1 | INTRODUCTION
It is well known that haemoglobin (Hb) in circulating red blood cells
(RBCs) acts as a high‐affinity depot or storage pool for nitric oxide
(NO)1 and that, cell‐free Hb, an even more avid scavenger of NO,
contributes to the pathology of haemolytic anaemias like sickle cell
disease, malaria and transfusion of older stored blood.2 Less well
known is that nitrite enzymatically reacts with deoxyhaemoglobin to
generate nitric oxide in the RBC, which serves as an “erythrocrine,”
that is endocrine carrier and exporter of NO. in the circulation under
low oxygen conditions.3
Platelets are disc‐shaped cell fragments, 1/14th the volume of
erythrocytes, that change shape and aggregate at wound sites to ini-
tiate clotting and stop bleeding in response to physical and chemical
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stimuli such as collagen,4 adenosine diphosphate (ADP), epinephrine,
thromboxane A2 (TxA2) and thrombin. In addition to sealing vascular
breaches, platelets are also implicated in the pathogenesis of hyper-
tension, hypercholesterolaemia, cigarette smoking,5 diabetes and
cancer6 and their activation predisposes to thrombotic vascular com-
plications, leading to ischaemia and the development of coronary,
cerebrovascular and peripheral artery disease. 7 Excessive activation,
therefore, is tightly regulated, mostly through the action of inhibitory
factors such as NO, released continually by eNOS (endothelial nitric
oxide synthase) in the endothelium (except under hypoxic conditions
when its activity is impaired), that limits both platelet adhesion to
the vascular wall and platelet aggregation by activation of cGMP/
PKG pathway, which in turn leads to reduction in concentration of
Ca2+ with vasodilation and increased blood flow.8,9 Nonetheless, a
common feature of endothelium dysfunction is reduced NO bioavail-
ability, which induces abnormal platelet activation leading to throm-
bus formation and vessel occlusion.
RRx‐001, a new class of aerospace‐derived anticancer and nor-
mal tissue cytoprotective agent,10 binds selectively and irreversibly
to an accessible and highly conserved thiol on haemoglobin called
beta (β) cysteine 93; this binding of RRx‐001 to Hb β cysteine 93
significantly accelerates the rate of reduction in endogenous nitrite,
which RBCs carry in bulk,11 to nitric oxide.12,13 In addition, to a
much lesser extent, one of the nitro groups on RRx‐001 is postu-
lated to be the site of a Nef‐like reaction, a standard reaction of
organic nitro derivatives,14 wherein nitric oxide is non‐enzymatically
released. This RRx‐001‐mediated hyperinduction of NO15 under
hypoxic conditions and lack of hypotensive side‐effects as well as
headache, facial flushing, etc.16 differentiates it from other nitric
oxide donors such as organic nitrates, S‐nitrosothiols, diazeniumdio-
lates‐NONOates, furoxans, zeolites, NO hybrid drugs and hydrox-
yurea17 that act systemically, resulting in potential toxicities.18 The
primary objective of this study was to investigate the potential anti-
aggregant and antithrombotic effects of RRx‐001, as an NO donor,
and to compare these ex vivo effects in whole blood and platelet‐
rich plasma (PRP) with those of diethylenetriamine NONOate
(DETA‐NONOate), which spontaneously releases nitric oxide in
aqueous solution. A diagram, which depicts NO release from RRx‐
001, DETA‐NONOate and eNOS in the endothelium, is shown in
Figure 1.
2 | METHODS
2.1 | Blood and reagents
Blood was collected from healthy volunteers after fasting state of at
least 3 hours. The venous blood samples were taken from healthy
volunteers, of 24 (mean 3 SD) years of age in tubes containing
sodium citrate in the ratio of 9:1 (vol per vol). Sodium nitrite
(NaNO2), adenosine 5′diphosphate (ADP), collagen and Dextran 500
were purchased from Sigma (St Louis, MO, USA). DETA‐NONOate
(diethylenetriamine NONOate) was purchased from Cayman Chemi-
cal (Ann Arbor, MI, USA). RRx‐001 was obtained from EpicentRx
(San Diego, CA, USA). The nitric oxide inhibitor 2‐(4‐carboxyphenyl)‐
4,4,5,5‐tetramethylimidazole‐1‐oxyl 3‐oxide (Carboxy‐PTIO) was pur-
chased from Sigma (St Louis). Luciferin‐luciferase reagent (Chrono‐
Lume) was purchased from Chrono‐Log Corporation (Howertown,
PA, USA). DETA‐NONOate was freshly prepared by dissolving in
0.01 mol/L NaOH and used within 1 day. Immediately before use,
DETA‐NONOate was diluted in phosphate‐buffered saline (PBS, pH
7.4). Sodium nitrite, ADP and Carboxy‐PTIO were prepared in PBS
at pH 7.4. Collagen was prepared in deionized water. Monoclonal
antibodies, FITC‐labelled anti‐human CD41a and PE‐labelled anti‐
human CD62P, were purchased from Becton Dickinson (San Jose,
CA, USA).
2.2 | RBC aggregation
Red blood cells were separated from the blood by centrifugation at
2000 g for 7 minutes and washed 3 times with 10 mmol/L phos-
phate‐buffered saline (PBS) (pH = 7.4). The washed RBCs were then
resuspended in PBS at a haematocrit of approximately 10%. RBC
suspensions were divided into aliquots and exposed to either RRx‐
001 (10 mg/kg), Dextran 500 (10 mg/kg) used as a positive control
to induce RBC aggregation or PBS (control sample) at 25°C for
10 minutes. The degree of RBC aggregation was determined from
duplicate measurements on a 20 μL blood sample with a photomet-
ric rheoscope (Myrenne Aggregometer®, Myrenne GmbH, Roetgen,
Germany), which gives the indices of RBC aggregation “M” during
stasis after shearing at 600 s−1. Briefly, this device measures the
changes in light transmission, which are observed when sheared
RBC suspensions are abruptly brought to a full stop. The decrease in
the optical signal reflects the formation of RBC aggregates.
2.3 | Coagulation studies
Coagulation studies were performed on plasma separated at 4°C
from citrated whole blood.
Measurement of the activated prothrombin time (aPTT), pro-
thrombin time (PTT), fibrinogen and platelets was determined by
standard commercial assays. Platelet aggregation was analysed on
an aggregometer. Platelets from PRP were incubated at 37°C, sub-
jected to stirring and stimulated with agonists: 1 mmol/L ADP,
3 mmol/L ADP, collagen and epinephrine. The effect of vehicle (no
treatment) and RRx‐001 (10 mg/mL) on the various tests was
determined.
2.4 | Platelet aggregation and ATP release
Whole blood was centrifuged at 1100 g for 10 minutes. The
upper portion was collected for PRP. The lower portion was cen-
trifuged further at 21 000 g for 10 minutes to obtain the platelet‐
poor plasma (PPP). The PRP was used for aggregation studies
within <3 hours after blood drawing. The effect of sodium nitrite,
RRx‐001 and DETA‐NONOate on platelet aggregation in PRP and
RP + erythrocytes was determined by the turbidimetric and
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impedance aggregometry, respectively. In turbidimetric experi-
ments, the PRP was pre‐incubated with 0.01‐100 mmol/L sodium
nitrite, RRx‐001 or DETA‐NONOate at 37°C for 5 minutes. In sep-
arate experiments, the PRP was pre‐incubated with 0.01‐
100 mmol/L sodium nitrite, RRx‐001 or DETA‐NONOate at 37°C
for 5 minutes in the presence 200 mmol/L Carboxy‐PTIO. Platelet
aggregation was induced by 8 mmol/L ADP. Platelet aggregation
was measured using a Platelet Aggregometer Model 560 (Chrono‐
Log Corporation). The increased light transmission was an indicator
of increased aggregation in PRP. In the impedance experiments,
platelet aggregation in PRP or PRP + erythrocytes was studied by
impedance aggregometry in which the change in electrical impe-
dance (in ohms, Ω) was monitored. The increase in the electrical
impedance of electrode correlated with increased aggregation. The
erythrocytes were added into PRP to produce a haematocrit of
1% and 20%. The haematocrit values in the mixture of PRP + ery-
throcytes were confirmed by the microhaematocrit centrifugation.
The PRP+erythrocyte samples were pre‐incubated at 37°C with
0.01‐100 mmol/L sodium nitrite, RRx‐001 or DETA‐NONOate at
37°C for 5 minutes in the presence or absence of Carboxy‐PTIO.
The ATP released from platelets was monitored by luminescence
aggregometer using a luciferin‐luciferase assay. The amount of
ATP was calculated from the luminescence signal of ATP standard
according to the manufacturing protocol. Additional, platelet aggre-
gation with 0.01‐100 mmol/L sodium nitrite using impedance mea-
surements, in PRP or PRP + erythrocytes, was performed at
haematocrit of 20% of pre‐incubated samples with RRx‐001 or
DETA‐NONOate at 37°C for 5 minutes in the presence or
absence of Carboxy‐PTIO. Lastly, platelet aggregation with 0.01‐
100 mmol/L sodium nitrite during normoxia (room air) and hypoxia
(5% O2) using impedance measurements, in PRP or PRP + erythro-
cytes were performed at haematocrit of 20% of pre‐incubated
samples with RRx‐001 or DETA‐NONOate at 37°C for 5 minutes
in the presence or absence of Carboxy‐PTIO.
2.5 | Measurement of cGMP levels in platelets
Washed platelets were prepared from PRP and resuspended in the
incubation buffer (130 mmol/L NaCl, 12 mmol/L NaHCO3,
0.34 mmol/L NaH2PO4, 2.9 mmol/L KCl, 1 mmol/L CaCl2, 0.8 mmol/L
MgCl2, 5 mmol/L Hepes, 5 mmol/L glucose, pH 7.4). The washed pla-
telet number was adjusted to 4500 cells/mL and incubated for
1 hour at room temperature before use. 0.1 mmol/L nitrite was
added into the platelet suspension in the presence or absence of
erythrocytes (20% haematocrit), and in the presence or absence of
erythrocytes (20% haematocrit) pre‐incubated with RRx‐001 for
5 minutes. After incubation with agonist and stirring at 37°C for
5 minutes, the samples were mixed with 5% trichloroacetic acid and
centrifuged at 18 000 g for 10 minutes. The supernatant was col-
lected and stored at 80°C until measurement. The cGMP levels were
measured by the enzyme‐linked immunoassay (Cayman Chemical,
Ann Arbor, MI, USA).
2.6 | Nitrite/nitrate levels in samples
Plasma proteins were removed by adding an equivolume of
methanol and centrifuged at 5: 15000 RPM (0.025 Gs) at 4°C.
Concentrations of nitrite and nitrate in the supernatant were mea-
sured with a NOx analyser (ENO‐20; Eicom, Kyoto, Japan). This
analyser combines the Griess method and high‐performance liquid
chromatography.
2.7 | Statistical analysis
All data are means ± SD. Statistical analysis was analysed by Graph-
Pad Prism version 6 (GraphPad software Inc., San Diego, CA, USA).
Correlation was analysed by Pearson's method. ANOVA with Tukey's
multiple comparison were used to compare with acceptable P‐value,
0.05.
F IGURE 1 A Diagram, which Depicts
Four Methods of NO Release, Leading to
Increased Blood Flow: (a) nitric oxide is
postulated to be released from RRx‐001
(formula shown below) directly via a Nef‐
like reaction; (b) RRx‐001 binds to the
betaCys93 residue on haemoglobin, which
accelerates the formation of nitric oxide
from deoxyhemoglobin in RBCs; (c)
spontaneous release of nitric oxide from a
NONOate in aqueous media; (d)
production of NO via eNOS in the
endothelium
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3 | RESULTS
3.1 | RRx‐001 had no effect on RBC rouleaux
formation or aggregation
In red blood cells exposed to RRx‐001, no rouleaux formation or
increased aggregation was observed compared with vehicle or
untreated RBCs, as shown in Figure 2.
3.2 | RRx‐001 modified ADP, collagen and
epinephrine‐induced platelet aggregation but not
coagulation parameters
At concentrations of 10 mg/mL, RRx‐001 did not affect coagulation
parameters (APTT, PTT and fibrinogen were all within normal range)
and, similarly, thrombocyte count was within the normal range
(278 ± 54 × 103/mm3). However, RRx‐001 non‐significantly attenu-
ated or modified platelet adhesion/aggregation induced by collagen,
epinephrine or ADP, as shown in Figure 3.
3.3 | The platelet inhibitory effects of RRx‐001 and
DETA‐NONOate are reversed by the addition of
CPTIO, a nitric oxide scavenger
Platelet aggregation was studied in platelet‐rich plasma (PRP). In PRP,
DETA‐NONOate and RRx‐001 both exhibited a dose‐dependent inhi-
bition of platelet aggregation induced by 8 μmol/L ADP; however, the
effect of DETA‐NONOate on platelet aggregation was much more
pronounced that RRx‐001. However, the antiplatelet effects of both
DETA‐NONOate and RRx‐001 were reversed by CPTIO, an NO scav-
enger, which suggests an NO‐mediated action. (Figure 4).
3.4 | The platelet inhibitory effects of RRx‐001 and
DETA‐NONOate are dependent on haematocrit
In platelet aggregation measured by impedance (electrical resistance),
the magnitude of effect for RRx‐001 and DETA‐NONOate varied
inversely with each other depending on the haematocrit. As RRx‐001
stimulates red blood cells to reduce nitrite to NO and since haemoglo-
bin scavenges nitric oxide, the effect of haematocrit on platelet inhibi-
tion was tested. The impedance aggregometry method was used
because RBCs interfered with the light transmission method. The inhi-
bitory effect of DETA‐NONOate on platelet aggregation decreased in
the presence of RBCs with a 20% haematocrit attenuating the effect
of DETA‐NONOate to a greater extent than a 1% haematocrit, pre-
sumably due to NO destruction by haemoglobin in RBCs. By contrast,
the inhibitory effect of RRx‐001 on platelet aggregation increased in
the presence of RBCs with a 20% haematocrit > than 1% haematocrit,
likely due to stimulation of the nitrite reductase function of deoxy-
haemoglobin, which converts nitrite to NO. However, irrespective of
the haematocrits, the antiplatelet effects of both DETA‐NONOate and
RRx‐001 were reversed by CPTIO. (Figure 5).
3.5 | The addition of nitrite enhanced the inhibitory
action of RRx‐001 on platelet activation
The potential effect of nitrite addition (0.1‐10 μmol/L) on the RRx‐
001‐mediated regulation of platelet activity, given that RRx‐001‐
F IGURE 2 A, Blood Smear for
Aggregation Studies Obtained from
Heparinized Human Blood Untreated or
Treated with Vehicle, RRx‐001 (10 mg/kg)
or Dextran 500 kDa (10 mg/kg in Sterile
Saline, Positive Control). From left to right
vehicle‐treated blood, RRx‐001‐treated
blood and Dextran‐treated blood. Clumping
and rouleaux formation is only seen with
Dextran, the positive control; B, RBC
aggregation index of human blood
untreated, or treated with Vehicle, RRx‐
001 (10 mg/kg) or Dextran 500 kDa
(10 mg/kg in sterile saline, positive control).
RBC aggregation index was unchanged
between untreated blood, vehicle‐treated
blood and RRx‐001 treated blood. Only
Dextran, the positive control, showed a
significant (P < 0.05) increase in RBC
clumping and aggregation (far right panel)
ORONSKY ET AL. | 5079
bound deoxyhaemoglobin reduces nitrite to NO, was examined. In
the presence of RBCs (20% haematocrit), increasing concentrations
of nitrite inhibited platelet aggregation for all 3 groups: vehicle, RRx‐
001 and DETA‐NONOate. However, the effect of nitrite on RRx‐
001‐inhibition was significantly greater compared to DETA‐NONO-
ate. In addition, the effect of nitrite on all 3 groups was diminished
in the presence of CPTIO (Figure 6).
4 | DISCUSSION
The main objective of this pilot study was to investigate ex vivo
the effects of RRx‐001 and DETA‐NONOate on platelet aggrega-
tion induced by ADP, epinephrine and collagen in whole blood
and PRP. The antiplatelet effects of RRx‐001 and DETA‐NONOate
varied depending on the dose and presence or absence of RBCs.
Consistent with its red blood cell‐based mechanism of action19 in
which RRx‐001 binds to Hb and catalyses the conversion of nitrite
to NO. from deoxyhaemoglobin, the antiplatelet effect of RRx‐001
increased at a higher haematocrit and was further enhanced with
the addition of nitrite; however, no effect on coagulation
parameters or RBC aggregation was observed. These doses of
RRx‐001 correspond to its plasma concentrations in patients with
cancer.
By contrast, the antiplatelet effect of DETA‐NONOate was more
pronounced in pure PRP and decreased as the haematocrit increased
since haemoglobin‐containing RBCs scavenge nitric oxide and reduce
its availability. The antiaggregatory actions of both RRx‐001 and
DETA‐NONOate were almost completely abrogated in the presence
of the NO inhibitor, CPTIO, irrespective of whether RBCs and nitrite
were present, which served to confirm the NO‐dependent mecha-
nism of action.
These antiaggregatory properties of RRx‐001, as an antitumour
agent in Phase 3 clinical trials, merit in vivo correlation, especially as
platelet activation is known to contribute to tumour invasion and
metastasis20 and a number of anticoagulants and antiaggregatory
agents have already been investigated for their possible anticancer
effects. While these ex vivo platelet aggregation studies are at best
a crude indicator of in vivo activity and involved blood collected
from healthy volunteers rather than hypercoagulable cancer patients,
F IGURE 3 Basic Coagulation and Platelet Aggregation Parameters with Untreated, Vehicle‐treated and RRx‐001‐treated Blood. RRx‐001
does not Affect APTT, PTT, Fibrinogen or Platelet Numbers Compared to Untreated Blood or Control. However, RRx‐001 appeared to
attenuate platelet aggregation in response to ADP, collagen and epinephrine. ADP, adenosine diphosphate; APTT, activated partial
thromboplastin time; PTT, partial thromboplastin time
F IGURE 4 Platelet Aggregation of Platelet‐rich Plasma Measured using % of Light Transition. Effects of RRx‐001 and DETA‐NONO in the
absence (left panel) and in the presence (right panel) of the nitric oxide scavenger, CPTIO. Each point represents the mean ± SEM of all
experiments. The platelets were incubated with test drugs for before stimulation with ADP, and aggregation was monitored thereafter. Results
are expressed as percent inhibition of aggregation relative to the untreated platelets CPTIO: 5,2‐(4‐carboxyphenyl)‐4,4,5,5‐
tetramethylimidazoline 1‐oxyl 3‐oxide
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it is nevertheless possible to interpret the results in the context of
multiple clinical trials for several different tumours types including
small cell lung cancer (SCLC), non‐small cell lung cancer (NSCLC),
glioblastoma (GBM), neuroendocrine and ovarian cancer in which so
far iegoonly one patient of 170 that has received RRx‐001 devel-
oped an arterial thromboembolic event (cerebrovascular accident or
CVA), resulting from enhanced platelet aggregation. From these
experiments, it seems reasonable to conclude that any relationship
F IGURE 5 Inhibition of Platelet Aggregation by DETA‐NONO Decreased in the Presence of Increasing Haematocrit whereas Inhibition of
Platelet Aggregation by RRx‐001 Increased in the Presence of Increasing Haematocrit. Platelet aggregation was induced by 8 μmol/L ADP.
CPTIO completely reversed the inhibition. All experiments were performed at 37°C
F IGURE 6 Nitrite+ red blood cells (RBCs) (20% Haematocrit) Inhibited ADP‐induced Platelet Aggregation. Nitrite was incubated in
PRP + RBCs in the presence or absence of CPTIO before induction of aggregation by ADP
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between RRx‐001 and the CVA event in this one patient is improba-
ble (although not impossible).
Currently, RRx‐001 is dosed as a single agent and in combination
with standard chemotherapy and radiation; its mechanism of anti-
cancer action is thought to be related to pan‐epigenetic inhibi-
tion21,22 and the repolarization of tumour associated macrophages
and neutrophils23; however, the synergistic activity between nitrite
and RRx‐001 on platelet aggregation suggests that co‐administration
with nitrite, which would lead to overproduction of NO. and other
genotoxic reactive nitrogen species under the hypoxic conditions
presumably endemic only to tumours, may not only result in
enhanced cytotoxicity but also improved safety, as patients with
cancer are prone to increased platelet activation and thromboem-
bolic events.
In conclusion, these data, which confirm previous observations
that RRx‐001 catalyses the conversion of nitrite to nitric oxide from
deoxyhaemoglobin24 suggest that RRx‐001, apart from its anticancer
effects and unlike all other known NO‐donating agents, reduces pla-
telet aggregation and protects against thromboembolism as haemo-
globin and haematocrit levels increase. Moreover, also unlike other
known NO‐donating agents, because RRx‐001 mediates increased
nitric oxide production under hypoxic conditions, NO is released
locally on demand where it is most needed when eNOS is impaired.
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